Host Genetic Background Modulates RON-Mediated Regulation of TLR4 Signaling in Tissue-Associated Macrophages

Toll-like receptors (TLRs) play a central role in initiating innate immune responses against microbial and viral pathogens, as well as endogenous danger signals released during cellular stress or necrosis. Among these, TLR4 recognizes lipopolysaccharide (LPS) from Gram-negative bacteria and various endogenous ligands, triggering robust inflammatory cascades. The magnitude and duration of TLR4 activation are tightly regulated to prevent excessive inflammation while ensuring effective host defense. Recent evidence highlights that host genetic background significantly influences TLR responsiveness, contributing to differences in susceptibility to infections, autoimmune diseases, and cancer. In this context, the receptor tyrosine kinase recepteur d’origine nantais (RON), activated by macrophage-stimulatory protein (MSP), emerges as a key modulator of macrophage function and immune signaling.

In tissue-resident macrophages, RON regulates essential processes such as motility, phagocytosis, and cytokine production. Importantly, RON has been shown to fine-tune TLR4-mediated inflammatory responses. This study reveals that the regulatory effect of RON on TLR4 signaling is profoundly influenced by mouse genetic background. Using peritoneal macrophages isolated from M2/Th2-polarized FVB mice and M1/Th1-polarized C57Bl6 mice, we demonstrate that RON exerts a potent suppressive effect on LPS-induced pro-inflammatory mediators—particularly tumor necrosis factor-alpha (TNF-α) and IL-12p40—only in FVB-derived macrophages. In contrast, this modulation is minimal in C57Bl6 cells, indicating a strain-specific functional divergence.

Global gene expression profiling further uncovers a novel mechanism: RON selectively represses the type-I interferon (IFN-I) gene signature in FVB macrophages following TLR4 stimulation. This suppression correlates with reduced TNF-α production, suggesting an indirect pathway involving IFN-b as a key intermediary.Fmoc-PNA-A(Bhoc)-OH In stock Indeed, neutralizing IFN-b antibodies significantly attenuated LPS-induced TNF-α release in FVB macrophages, confirming the dependence on IFN-b for maximal TNF-α output.4,6-Dibromoisophthalic acid In stock This regulatory axis is absent in C57Bl6 macrophages, where IFN-I response kinetics are delayed and RON has limited impact.PMID:35240971

The downstream signaling pathways activated by RON—including phosphorylation of p42/44 MAPK, AKT, and STAT3—are conserved across both genetic backgrounds, although minor kinetic differences exist. Notably, RON does not affect early TLR4-dependent NF-κB activation or p38 MAPK phosphorylation, underscoring that its influence is selective and occurs through non-canonical cross-talk rather than direct interference with core TLR4 machinery.

In vivo relevance was confirmed using carcinogen-induced tumor models. RON kinase-deficient FVB mice exhibited marked resistance to DMBA/TPA-induced skin papilloma formation and methylcholanthrene (MCA)-induced fibrosarcoma development. This protective effect was not observed in RON-KD C57Bl6 mice, highlighting the critical role of genetic context in shaping immune outcomes. Histological analysis revealed abundant macrophage infiltration in papillomas from wild-type FVB mice, consistent with their pro-tumorigenic role, whereas RON deficiency disrupted this supportive microenvironment.

These findings illustrate that RON’s immunomodulatory capacity is not universal but is instead genetically constrained. The ability of RON to suppress IFN-I signaling and promote an M2-like phenotype is restricted to specific genetic backgrounds, such as FVB, which predispose toward Th2 immunity. This variability underscores the importance of considering host genetics when targeting RON therapeutically in autoimmune disorders or cancer. Future strategies aiming to modulate RON signaling must account for genetic heterogeneity to achieve predictable and effective clinical outcomes.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com